Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 21OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × fosaprepitant × Clear all
NCT05509634 2023-10-27

Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 3 Completed
754 enrolled

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡